About
Outcome data on infants born to patients with hepatitis B virus (HBV) infection are collected, analyzed, and reported by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Perinatal Hepatitis B Prevention Program (PHBPP),1 which funds 64 jurisdictions to identify pregnant patients with HBV infection and to manage the healthcare of their infants to improve receipt of post-exposure prophylaxis (PEP) (hepatitis B vaccine birth dose and hepatitis B immune globulin), hepatitis B vaccine series completion, and post-vaccination serologic testing.
Locations
Participating jurisdictions are the 50 United States, District of Columbia, five cities (Chicago, Houston, New York City, Philadelphia, and San Antonio), five US territories (American Samoa, Guam, N. Mariana Islands, Puerto Rico, and US Virgin Islands), and three freely associated states (Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau).
What's collected
Data in this report are from the reporting period for the 2021 birth cohort, followed from January 1, 2021–December 31, 2022, and only include infants whose care was managed by the program.
Follow-up time for infants varies in length depending on their date of birth. Because of differences in the states and jurisdictions participating, not all cases among infants identified as hepatitis B surface antigen (HBsAg) positive within the PHBPP 1are reported to the ÐÇ¿ÕÓéÀÖ¹ÙÍø National Notifiable Diseases Surveillance System (NNDSS).
- Koneru A, Fenlon N, Schillie S, et al. Pediatrics March 2021; 147(3) e20201823.